An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Exclusion Criteria

• •Clinically significant liver disease
• •Patients known to be human immunodeficiency virus seropositive and have a CD4 count \<200 cells/μL
• •History of venous thromboembolism
• •Current serious mental illness that, in the judgment of the Investigator, may compromise patient safety, ability to participate in all study assessments, or study integrity
• •Clinically relevant history or presence of cardiovascular, respiratory, gastrointestinal, renal, neurological, inflammatory, or other diseases that, in the judgment of the Investigator, precludes study participation